Cladribine: not just another purine analogue?

Bibliography

• Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;18(2(7786)):1067-9
   Google Scholar
• Cohen A, Hirschhorn R, Horowitz SD, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 1978;75(1):472-6
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980;77(11):6865-9
   PubMed Web of Science ®Google Scholar
• Cottam HB, Kazimierczuk Z, Geary S, et al. Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2′-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure. J Med Chem 1985;28(10):1461-7
   PubMed Web of Science ®Google Scholar
• Laboratories B. Cladribine Package Insert. 2006
   Google Scholar
• Cheson B. The purine analogs–a therapeutic beauty contest. J Clin Oncol 1992;10(5):868-71
   PubMed Web of Science ®Google Scholar
• Eriksson S, Arner E, Spasokoukotskaja T, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul 1994;34:13-25
   PubMedGoogle Scholar
• Hentosh P, Grippo P. Template 2-chloro-2′-deoxyadenosine monophosphate inhibits in vitro DNA synthesis. Mol Pharmacol 1994;45(5):955-61
   PubMed Web of Science ®Google Scholar
• Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci USA 1998;95(16):9567-71
   PubMed Web of Science ®Google Scholar
• Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75(2):377-83
   PubMed Web of Science ®Google Scholar
• Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000;275(1):29-34
   PubMed Web of Science ®Google Scholar
• Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma 2003;44(10):1705-12
   PubMed Web of Science ®Google Scholar
• Jamaluddin MD, Chen I, Yang F, et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 2007;110(10):3648-55
   PubMed Web of Science ®Google Scholar
• Wyczechowska D, Fabianowska-Majewska K. The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochem Pharmacol 2003;65(2):219-25
   PubMed Web of Science ®Google Scholar
• Yu MK. Epigenetics and chronic lymphocytic leukemia. Am J Hematol 2006;81(11):864-9
   PubMed Web of Science ®Google Scholar
• Yu MK, Szabo A, Bergonia H, et al. Phillips, Global DNA hypermethylation in chronic lymphocytic leukemia correlates with progressive disease [abstract 5006]. Blood (ASH Annual Meeting Abstracts) 2005;106
   Google Scholar
• Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 2003;109(1):80-8
   PubMed Web of Science ®Google Scholar
• Margaret K, Yu JTM, Martha G, et al. Phillips, DNA Methylation Inhibitors Upregulate MiRNA Expression in Patients with Chronic Lymphocytic Leukemia [abstract 2257]. Blood (ASH Annual Meeting Abstracts) 2006;108
   Google Scholar
• Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21(9):1050-63
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Jillella A, et al. Combined epigenetic therapy with the novel histone methyl transferase EZH2 inhibitor 3-deazaneplanocin and histone deacetylase inhibitor panobinostat exerts synergistic activity against human mantle cell lymphoma cells [abstract 3622]. Blood (ASH Annual Meeting Abstracts) 2008;112
   Google Scholar
• Bouzar AB, Boxus M, Defoiche J, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009;144(1):41-52
   PubMed Web of Science ®Google Scholar
• Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 1991;51(20):5570-2
   PubMed Web of Science ®Google Scholar
• Kearns CM, BR, Santana VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994;54(5):1235-9
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322(16):1117-21
   PubMed Web of Science ®Google Scholar
• Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. Jpn J Clin Oncol 1997;27(3):146-53
   PubMed Web of Science ®Google Scholar
• Sonderegger T, BD, Cerny T, Lauterburg BH. Pharmacokinetics of 2-chloro-2′-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol 2000;46(1):40-2
   PubMed Web of Science ®Google Scholar
• Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994;330(10):691-7
   PubMed Web of Science ®Google Scholar
• Guchelaar HJ, Richel DJ, Schaafsma MR. Clinical and toxicological aspects of the antineoplastic drug cladribine: a review. Ann Hematol 1994;69(5):223-30
   PubMed Web of Science ®Google Scholar
• Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989;73(1):38-46
   PubMed Web of Science ®Google Scholar
• Larson RA, Mick R, Spielberger RT, et al. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol 1996;14(1):188-95
   PubMed Web of Science ®Google Scholar
• Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy. Eur J Haematol 2001;66(1):7-10
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106(1):241-6
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92(6):1918-26
   PubMed Web of Science ®Google Scholar
• Piro LD, Ellison DJ, Saven A. The scripps clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14(1):121-5
   PubMedGoogle Scholar
• Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83(10):2906-11
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18(9):1476-81
   PubMed Web of Science ®Google Scholar
• von Rohr A, Schmitz SF, Tichelli A, et al; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002;13(10):1641-9
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov/NCT00781235
   Google Scholar
• Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104(11),10(11):2442-8
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118(3):195-8
   PubMed Web of Science ®Google Scholar
• Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol 1998;103(3):690-5
   PubMed Web of Science ®Google Scholar
• Hellmann A, Lewandowski K, Zaucha JM, et al. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol 1999;63(1):35-41
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jager G, Baldinger C, et al. First-line treatment of Waldenström's disease with cladribine. Ann Hematol 1997;74(1):7-10
   PubMed Web of Science ®Google Scholar
• Blum KA, Johnson JL, Niedzwiecki D, et al; Cancer and Leukemia Group B Study 9153. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer 2006;107(12):2817-25
   PubMed Web of Science ®Google Scholar
• Saven A, Emanuele S, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995;86(5):1710-6
   PubMed Web of Science ®Google Scholar
• Laurencet F, Ballabeni P, Rufener B, et al; Swiss Group for Clinical Research (SAKK). The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol 2007;117(1):40-7
   PubMed Web of Science ®Google Scholar
• Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992;10(3):371-7
   PubMed Web of Science ®Google Scholar
• Kalinka-Warzocha E, Wajs J, Lech-Maranda E, et al.; Polish Lymphoma Research Group. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer 2008;113(2):367-75
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107(7):1542-50
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Jäger E, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol 1999;10(1):115-7
   PubMed Web of Science ®Google Scholar
• Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113(1):108-16
   PubMed Web of Science ®Google Scholar
• Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001;40(5-6):551-64
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003;17(2):323-7
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993;11(4):679-89
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96(8):2723-9
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia – updated results of the multicentre study of 378 patients. Br J Haematol 2000;108(2):357-68
   PubMed Web of Science ®Google Scholar
• Karin A, Karlsson MS, Jönsson V, et al. Cladribine (CdA) Gives Longer Response Duration Than Fludarabine (F) and High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia (CLL). First Results from the International Randomized Phase III Trial [abstract 630]. Blood (ASH Annual Meeting Abstracts) 2007;110
   Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit 2005;11(10):171-9
   Google Scholar
• Robak T, Smolewski P, Cebula B, et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79(2):107-13
   PubMed Web of Science ®Google Scholar
• Morabito F, Stelitano C, Callea I, et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996;81(3):224-31
   PubMed Web of Science ®Google Scholar
• Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327(15):1056-61
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Wawrzyniak E, et al. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. Cancer 2009;115(1):94-100
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Bush R, Hopfinger G, et al.; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885-91
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al.; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370(9583):230-9
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25(7):799-804
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al. Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial [abstract 781]. Blood (ASH Annual Meeting Abstracts) 2008;112
   Google Scholar
• O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994;330(5):319-22
   PubMed Web of Science ®Google Scholar
• Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003;44(3):391-409
   PubMed Web of Science ®Google Scholar
• Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001;19(11):2804-11
   PubMed Web of Science ®Google Scholar
• Vahdat L, Wong ET, Wile MJ, et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994;84(10):3429-34
   PubMed Web of Science ®Google Scholar
• Gordon MS, Young ML, Tallman MS, et al. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res 2000;24(10):871-5
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, et al.; Polish Adult Leukemia Group. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008;80(2):115-26
   PubMed Web of Science ®Google Scholar
• Jerzy Holowiecki SG, Kyrcz-Krzemien S, Kuliczkowski K, et al. Addition of cladribine to the standard daunorubicine – cytarabine (DA 3+7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60 Y: a multicenter, randomized, phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 patients [abstract 133]. Blood (ASH Annual Meeting Abstracts) 2008;112
   Google Scholar
• Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med 1994;121(6):430-2
   PubMed Web of Science ®Google Scholar
• Weitzman S, Wayne AS, Arceci R, et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999;33(5):476-81
   PubMedGoogle Scholar
• Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 1997;29(4):288-92
   PubMedGoogle Scholar
• Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 2004;77(3):209-14
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Rodriguez M. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Mayo Clin Proc 1997;72(7):665-78
   PubMed Web of Science ®Google Scholar
• Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother 2006;40(10):1814-21
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54(5):1145-55
   PubMed Web of Science ®Google Scholar
• Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996;93(4):1716-20
   PubMed Web of Science ®Google Scholar
• Available from: http://www.mscare.org/cmsc/Informs-Serono-Cladribine-Tablets.html
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term= cladribine+and+MS
   Google Scholar
• Davis JC Jr, Austin H III, Boumpas D, et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998;41(2):335-43
   PubMed Web of Science ®Google Scholar
• Ilyas W, Myers D, Mann R, Seraly MP. Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia. J Am Acad Dermatol 1999;41(2 pt 2):316-8
   PubMed Web of Science ®Google Scholar
• Valencak J, Trautinger F, Fiebiger WC, Raderer M. Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine. Ann Hematol 2002;81(11):662-5
   PubMed Web of Science ®Google Scholar
• Schirmer M, Mur E, Pfeiffer KP, et al. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol 1997;26(5):376-9
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood 2003;101(3):943-5
   PubMed Web of Science ®Google Scholar
• Orr RM, Talbot DC, Aherne WG, et al. 2′-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2′-deoxyadenosine resistance in lymphoid cell lines. Clin Cancer Res 1995;1(4):391-8
   PubMed Web of Science ®Google Scholar
• Månsson E, Spasokoukotskaja T, Sällström J, et al. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res 1999;59(23):5956-63
   PubMed Web of Science ®Google Scholar
• Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106(1):78-85
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Spychala J, Mitchell BS. Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance. J Biol Chem 2001;276(13):10498-504
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993;81(3):597-601
   PubMed Web of Science ®Google Scholar
• Carson DA, Carrera CJ, Wasson DB, Iizasa T. Deoxyadenosine-resistant human T lymphoblasts with elevated 5′-nucleotidase activity. Biochim Biophys Acta 1991;1091(1):22-8
   PubMed Web of Science ®Google Scholar
• Lotfi K, Mansson E, Chandra J, et al. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br J Haematol 2001;113(2):339-46
   PubMed Web of Science ®Google Scholar
• Choy BK, McClarty GA, Chan AK, et al. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations. Cancer Res 1988;48(8):2029-35
   PubMed Web of Science ®Google Scholar
• Cardoen S, Van Den Neste E, Smal C, et al. Resistance to 2-chloro-2′-deoxyadenosine of the human B-cell leukemia cell line EHEB. Clin Cancer Res 2001;7(11):3559-66
   PubMed Web of Science ®Google Scholar
• Lang TT, Selner M, Young JD, Cass CE. Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol Pharmacol 2001;60(5):1143-52
   PubMed Web of Science ®Google Scholar
• Gati WP, Paterson AR, Belch AR, et al. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk Lymphoma 1998;32(1-2):45-54
   PubMed Web of Science ®Google Scholar
• Pérez-galán P, Marzo I, Giraldo P, et al. Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia 2002;16(10):2106-14
   PubMed Web of Science ®Google Scholar
• Chandra J, Mansson E, Gogvadze V, et al. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood 2002;99(2):655-63
   PubMed Web of Science ®Google Scholar
• Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995;1(4):385-90
   PubMed Web of Science ®Google Scholar
• Albertioni F, Lindemalm S, Reichelova V, et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 1998;4(3):653-8
   PubMed Web of Science ®Google Scholar
• Yu M, Epner E. The epigenetics of mantle cell lymphoma. Curr Treat Options Oncol 2007;8:375-81
   PubMedGoogle Scholar